Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates
09:55pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for th
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
02:32pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.2
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial
10:50am, Monday, 18'th Jul 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vi
Zacks.com featured highlights include Eagle Pharmaceuticals, Cabot, Meritage Homes, Griffon, and APA
03:31pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Eagle Pharmaceuticals, Cabot, Meritage Homes, Griffon, and APA are part of Screen of the Week article.
Press the Buy Button on These 5 High Earnings Yield Picks Now
11:26am, Wednesday, 01'st Jun 2022 Zacks Investment Research
One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.
Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker
10:50am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- -- Expect
Press the Buy Button on These 5 High Earnings Yield Picks Now
09:02am, Wednesday, 01'st Jun 2022
One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.
Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference
10:50am, Thursday, 26'th May 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian C
Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference
06:50am, Thursday, 26'th May 2022
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cah
Eagle Pharmaceuticals (EGRX) Q1 2022 Earnings Call Transcript
05:00pm, Monday, 09'th May 2022 The Motley Fool
EGRX earnings call for the period ending March 31, 2022.
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2022 Results - Earnings Call Transcript
12:25pm, Monday, 09'th May 2022
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - Founder, President, CEO & Director Brian Cahill
Eagle Pharmaceuticals Reports First Quarter 2022 Results
10:50am, Monday, 09'th May 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three months ended Marc
Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates
09:50am, Monday, 09'th May 2022
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
03:07pm, Wednesday, 04'th May 2022 Zacks Investment Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
12:47pm, Wednesday, 04'th May 2022
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
